Education
About Us
Working with TipRanks
Follow Us
Anavex Life Sciences (AVXL)
NASDAQ:AVXL
AVXL Stock Chart & Stats
$3.93
-$1.39(-10.33%)
At close: 4:00 PM EST
$3.93
-$1.39(-10.33%)
Day’s Range― - ―
52-Week Range$2.86 - $13.99
Previous CloseN/A
Volume1.46M
Average Volume (3M)1.43M
Market Cap
$364.20M
Enterprise Value$242.18M
Total Cash (Recent Filing)$131.75M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.46
Next Earnings
May 07, 2026EPS Estimate
-0.1Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.06
Shares Outstanding92,671,760
10 Day Avg. Volume1,569,979
30 Day Avg. Volume1,429,509
Financial Highlights & Ratios
PEG Ratio-4.26
Price to Book (P/B)8.00
Price to Sales (P/S)0.00
P/FCF Ratio-19.44
Enterprise Value/Market Cap0.66
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-8.39
Forecast
1Y Price Target
$20.00Price Target Upside408.91% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.51
Revenue Forecast (FY)$221.71M
Bulls Say, Bears Say
Bulls Say
Clinical Efficacy And Safety ProfileClinical data showing meaningful slowing of cognitive decline and a favorable safety and tolerability profile, including no amyloid‑related imaging abnormalities, bolster blarcamesine's therapeutic value proposition.
EMA Re‑examination And PrecedentA formal EMA re‑examination by a new rapporteur team, together with precedent for reversed negative opinions in Alzheimer's treatments, offers a tangible route to reconsider European approval prospects for blarcamesine.
Regulatory Engagement With FDAFDA reviewers' invitation to discuss clinical trial results and possible development pathways signals regulatory receptivity and may support a pathway toward a New Drug Application for blarcamesine.
Bears Say
Negative CHMP Opinion ImpactThe CHMP's negative trend vote on the Marketing Authorisation Application lowers the likelihood of a swift European approval and creates downward pressure on expectations for the program.
Potential Requirement For Additional TrialsRegulators could demand additional clinical studies before granting approval, which would delay market access for blarcamesine and increase program costs and execution risk.
Uncertainty Over Clinical EndpointsQuestions about the sensitivity of key outcome measures, such as ADCS‑ADL, introduce uncertainty about whether trial endpoints will satisfy regulators and payers and could complicate approval discussions.
Anavex Life Sciences News
AVXL FAQ
What was Anavex Life Sciences’s price range in the past 12 months?
Anavex Life Sciences lowest stock price was $2.86 and its highest was $13.99 in the past 12 months.
What is Anavex Life Sciences’s market cap?
Anavex Life Sciences’s market cap is $364.20M.
When is Anavex Life Sciences’s upcoming earnings report date?
Anavex Life Sciences’s upcoming earnings report date is May 07, 2026 which is in 77 days.
How were Anavex Life Sciences’s earnings last quarter?
Anavex Life Sciences released its earnings results on Feb 09, 2026. The company reported -$0.06 earnings per share for the quarter, beating the consensus estimate of -$0.123 by $0.063.
Is Anavex Life Sciences overvalued?
According to Wall Street analysts Anavex Life Sciences’s price is currently Undervalued.
Does Anavex Life Sciences pay dividends?
Anavex Life Sciences does not currently pay dividends.
What is Anavex Life Sciences’s EPS estimate?
Anavex Life Sciences’s EPS estimate is -0.1.
How many shares outstanding does Anavex Life Sciences have?
Anavex Life Sciences has 92,671,760 shares outstanding.
What happened to Anavex Life Sciences’s price movement after its last earnings report?
Anavex Life Sciences reported an EPS of -$0.06 in its last earnings report, beating expectations of -$0.123. Following the earnings report the stock price went up 6.098%.
Which hedge fund is a major shareholder of Anavex Life Sciences?
Currently, no hedge funds are holding shares in AVXL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Anavex Life Sciences Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$20.00 (408.91% Upside)
$20.00 (408.91% Upside)
Blogger Sentiment
Bullish
AVXL Sentiment 100%
Sector Average ―
Sector Average ―
Crowd Wisdom
Very Negative
Last 7 Days ▲ 0.1%
Last 30 Days ▼ 7.4%
Last 30 Days ▼ 7.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-53.60%
12-Months-Change
Fundamentals
Return on Equity
-33.63%
Trailing 12-Months
Asset Growth
7.21%
Trailing 12-Months
Company Description
Anavex Life Sciences
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patients with Rett syndrome; Phase II clinical trial for the treatment of Parkinson's disease; and preclinical clinical trials to treat epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple sclerosis, and tuberous sclerosis complex. The company's drug candidate also comprises ANAVEX 3-71, which is in Phase I clinical trial for the treatment of frontotemporal dementia and other dementia indications; and preclinical clinical trials for the treatment of neurodegenerative diseases, such as Alzheimer's and Parkinson's diseases. Its preclinical drug candidates include ANAVEX 1-41, a sigma-1 receptor agonist for the treatment of depression, stroke, Parkinson's, and Alzheimer's diseases; ANAVEX 1066, a mixed sigma-1/sigma-2 ligand for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.
AVXL Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presents a cautiously optimistic tone: the company reports a strong cash position with multi-year runway, notable reductions in burn, positive clinical signals (especially in the AB-clear precision-medicine subgroup) and constructive regulatory engagement with the FDA. However, the CHMP negative opinion, a missed ADCS-ADL endpoint in the original EU submission, and remaining execution and regulatory obligations (including potential confirmatory post-approval studies) are meaningful near-term risks. Overall, positive operational and scientific developments outweigh the regulatory setbacks, but outcomes remain contingent on ongoing reexamination and further regulatory interactions.View all AVXL earnings summariesAVXL Stock 12 Month Forecast
Average Price Target
$20.00
▲(408.91% Upside)
Technical Analysis
Galectin Therapeutics
―
Rocket Pharmaceuticals
―
Cellectis SA
―
Autolus Therapeutics
―
PepGen Inc.
―
Ownership Overview
3.23% Insiders
7.78% Mutual Funds
2.37% Other Institutional Investors
72.98% Public Companies and
Individual Investors